TXG (10x Genomics) Tariff Resilience Score: 7/10 (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TXG 10x Genomics Inc TXG
62 GF Score
Price $41.78
GF Value $18.93
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is 10x Genomics Tariff Resilience Score?

10x Genomics TXG -2.29% 62 Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $18.93 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 672 Healthcare Providers & Services companies, 10x Genomics ranks better than 89.29% on this metric.

10x Genomics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

10x Genomics has 10x Genomics, involved in life sciences, faces moderate tariff risks on imported lab equipment. Its innovative products and strong market position provide some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes 10x Genomics might have Highly Resilient.

10x Genomics  (NAS:TXG) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

10x Genomics Tariff Resilience Score Related Terms

TXG vs DOCS, WAY, PRVA: Tariff Resilience Score Comparison

For the Health Information Services subindustry, 10x Genomics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

10x Genomics Tariff Resilience Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Tariff Resilience Score falls into.


TXG
62GF Score
10x Genomics Inc TXG
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
10x Genomics (TXG) has a Tariff Resilience Score of 7 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, 10x Genomics ranks #72 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 10.7%.
Is 10x Genomics' Tariff Resilience Score too high?
10x Genomics' current Tariff Resilience Score is 7. Based on the distribution chart, 10x Genomics ranks #72 out of 672 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Tariff Resilience Score compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #72 out of 672 companies for Tariff Resilience Score. This places 10x Genomics in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Healthcare Providers & Services company?
A good Tariff Resilience Score depends on the Healthcare Providers & Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. 10x Genomics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.93, compared to a current price of $41.78 — trading 120.7% above its estimated fair value. The current Tariff Resilience Score is 7. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For 10x Genomics (TXG), the current Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 10x Genomics (TXG) Overvalued in 2026?

Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued. The current stock price of $41.78 is trading 120.7% above its estimated GF Value™ of $18.93. GuruFocus considers 10x Genomics to be Significantly Overvalued.

Key valuation signals for TXG:

  • Tariff Resilience Score: 7
  • GF Value™: $18.93 vs. price of $41.78 (120.7% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

10x Genomics Business Description

Other Exchanges 0A88:UK1KJ:Germany
Address 6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score

Get the complete analysis for TXG

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.78
Price
$18.93
GF Value